Heart disease suPAR star – Dr Janice Chew-Harris

We recently caught up with Dr Janice Chew-Harris, recipient of a $94,788, 2019 CMRF Major Project Grant for her project titled, “suPAR in cardiovascular disease“.

Janice explains what suPAR (soluble urokinase plasminogen activator receptor) means for patients and the doctors treating them, and her reasons for choosing heart disease as her research speciality at the Christchurch Heart Institute at the University of Otago, Christchurch.

“suPAR is an interesting protein on its own. It can exist in circulation as a full-length protein or as smaller truncated forms. These forms, either full-length or smaller forms may be present depending on cardiovascular disease progression. Therefore, my CMRF project’s goal is to determine whether the presence of suPAR forms may vary and may actually be more specific for certain cardiovascular disease subgroup” – Dr Janice Chew-Harris

For more information on heart disease, and to support this research project, click here

Stay in touch with CMRF

// Get all the latest news and insights to your inbox